Related Experiment Video
Updated: May 1, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A
A Díaz Rodríguez1, N Murga, M Camafort-Babkowski
1Centro de Salud de Bembibre, Bembibre, Spain.
Insights
Therapeutic inertia (TI) in managing high-risk hypercholesterolemia significantly increases the risk of ischemic events. Addressing TI in primary care is crucial for preventing cardiovascular incidents.
Area of Science:
- Cardiology
- Primary Care Medicine
- Public Health
Background:
- Therapeutic inertia (TI) is prevalent in managing vascular risk factors.
- The impact of TI on ischemic events requires further investigation.
- This study focuses on TI in hypercholesterolemia management.
Purpose of the Study:
- To investigate the relationship between therapeutic inertia in hypercholesterolemia treatment and the incidence of ischemic events.
- To assess the role of TI in high-risk hypercholesterolemic patients within Spanish primary care.
Main Methods:
- An observational, multicenter, case-control study involving 70 primary care centers in Spain.
- 235 high-risk hypercholesterolemic patients with a recent first ischemic event (cases) were matched with 235 controls.
- An 18-month observation period prior to the event/recruitment was analyzed.
Main Results:
- Therapeutic inertia at baseline was slightly higher in cases (39.7%) versus controls (34.8%), though not statistically significant.
- Multivariate analysis revealed TI at baseline significantly associated with ischemic events (OR 2.18).
- Family history of premature vascular disease and uncontrolled hypertension also independently predicted ischemic events.
Conclusions:
- Therapeutic inertia in high-risk hypercholesterolemic patients undergoing primary prevention doubles the short-term risk of ischemic events.
- Effective management of hypercholesterolemia in primary care is essential to mitigate ischemic event risk.
- Addressing therapeutic inertia is a key target for improving cardiovascular outcomes.
Background:
The frequency of therapeutic inertia (TI) is very high in the management of vascular risk factors, although its impact on the incidence of ischaemic events is not well-established. Our aim was to investigate the relationship between TI in the treatment of hypercholesterolaemia and the appearance of ischaemic events.
Methods:
An observational, multicentre, case-control study was conducted in 70 primary care centres in Spain. Case subjects (n = 235) were high-risk hypercholesterolaemic patients (both genders, ≥ 18 years) who had had a first event in the 12 months prior to recruitment. They were matched with 235 controls (by vascular risk, age and gender). The observation period was 18 months prior to the onset of a first event (cases) or to date of recruitment (control subjects).
Results:
The TI in the basal visit (an average of 7.8 months before the event) was slightly higher in cases than in controls (39.7% vs. 34.8%, NS). However, the accumulated TI was similar in both groups (70.7% for cases and 73.95% for controls, NS). The multivariate analysis, taking ischaemic events as the dependent variable, showed that the TI at baseline visit was significantly associated with the development of the event [OR 2.18 (95% CI 1.04-4.51), p < 0.05]. Other variables also associated with the ischaemic event were a family history of premature vascular disease [OR 3.38 (95% CI 1.35-8.49), p < 0.05] and uncontrolled hypertension [OR 2.35 (95% CI 1.02-5.43), p < 0.05].
Conclusion:
The TI in high-risk hypercholesterolaemic patients in primary prevention in Spanish primary care centres doubled the risk of an ischaemic event in the short term.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
